Restaurant Brands International Inc. Common Shares vs State Street SPDR S&P Biotech ETF — how do they compare? Restaurant Brands International Inc. Common Shares trades at $70.94 (market cap $24.56B), while State Street SPDR S&P Biotech ETF trades at $153.62 (market cap $10.11B). The key difference: Restaurant Brands International Inc. Common Shares is far larger — about 2.4× State Street SPDR S&P Biotech ETF's market cap, and Restaurant Brands International Inc. Common Shares pays a 3.68% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Restaurant Brands International Inc. Common Shares for 1 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| QSR | XBI | |
|---|---|---|
Market Cap | $24.56B | $10.11B |
Volume | 3,480,368 | 12,903,266 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $81.67 | $169.55 |
52-Week Low | $65.69 | $104.99 |
Typical Hold Time | 1 Days | 38 Days |
Enterprise Value | $39.17B | — |
Dividend Yield | 3.68% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Trailing returns across standard periods
Restaurant Brands International owns and franchises quick-service restaurant brands, including Burger King, Tim Hortons, Popeyes, and Firehouse Subs.
Read more on QSR →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →